Ipamorelin, as a ghrelin receptor agonist, can simulate the secretion of ghrelin from the gastrointestinal tract, increasing patients' appetite and weight
1000 mg **
It modulates GABA receptors allosterically, influences dopamine and serotonin receptor activity, enhances enkephalin levels, and reduces neuroinflammation, all through a single compound
Key Dates Include: Pre-release: December 4, 2024 Open for proposal submissions: January 8, 2025 DSIP Topic Q&A Closure: January 22, 2025, at 10:00 AM MT Close for proposal submissions: February 5, 2025, at 10:00 AM MT Participating DoD Components: Department of the Navy (Navy) Department of the Air Force (Air Force) Defense Health Agency (DHA) Missile Defense Agency (MDA) For further details on active topics and the submission process, you can explore the DoDs SBIR/STTR portal here